Broadcom stock dips to $320 as Intel shock hits chips; Fed week and VMware dispute loom
24 January 2026
1 min read

Broadcom stock dips to $320 as Intel shock hits chips; Fed week and VMware dispute loom

New York, January 24, 2026, 10:06 (EST) — Market closed.

  • Shares of Broadcom ended Friday 1.7% lower, closing at $320.05 after fluctuating between $314.19 and $326.90 during the session
  • After Intel’s weak outlook, chip sentiment turned choppy as investors prepared for a Fed decision and a packed earnings week
  • A Fidelity settlement involving access to Broadcom’s VMware software has reignited concerns over contract disputes

Shares of Broadcom Inc (AVGO.O) slipped 1.7% to finish at $320.05 on Friday, on volume around 30.3 million. The stock swung between a low of $314.19 and a high of $326.90 during the session.

Why it matters now: Broadcom is at the heart of the AI trade debate—investors are scrutinizing if data center spending is finally translating into profits. Rate expectations continue to sway tech valuations. Yung-Yu Ma, chief investment strategist at PNC Financial Services Group, described the recent market swings as a “short but steep roller-coaster ride.” Meanwhile, Franklin Templeton’s Chris Galipeau cautioned that the S&P 500’s valuation “had better be met” by earnings. 1

Intel shares plunged 17% on Friday after the company forecasted quarterly revenue and profit below market expectations, citing challenges in meeting demand for server chips powering AI data centers. Julian McManus, portfolio manager on Janus Henderson’s Global Alpha Equity team, called it a “show-me” period. 2

Fidelity Investments announced it has settled a lawsuit claiming Broadcom threatened to block access to VMware’s “business-critical” virtualization software, which enables firms to run multiple virtual servers on one physical machine. Broadcom has agreed to continue supplying these services and software to a Fidelity subsidiary. A Fidelity spokesperson confirmed the dispute won’t affect its operations. 3

Broadcom’s tale splits into two: semiconductors driven by cloud and networking demand, and infrastructure software anchored by VMware. These businesses rarely pause together, and each can push the stock one way or the other.

As Monday’s reopen approaches, traders will be eyeing any spillover from Intel’s warning across the chip sector. The key question: Is this just an Intel issue, or a sign of softer demand? Broadcom usually tracks the data-center group, shifting with risk-on or risk-off flows.

The “Magnificent Seven” mega-cap tech giants still hold sway over index moves. When they boost AI budget talks, chip suppliers often get a lift. But a hint of belt-tightening, and the momentum can vanish quickly.

The risks stand out clearly. If the Federal Reserve shifts to a hawkish stance, rate-sensitive tech multiples could take a hit. Plus, fresh customer resistance to VMware’s contract terms might keep legal challenges and renewal doubts in the spotlight.

The Federal Reserve’s policy decision on Jan. 28 at 2:00 p.m. ET stands out as the week’s clearest scheduled catalyst, with Chair Jerome Powell’s press conference set for 2:30 p.m. ET. 4

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week
Previous Story

Eli Lilly stock slips as obesity-drug headlines pile up ahead of next week

Tencent stock slips into weekend as 0700.HK lags tech gauge — what to watch before Monday
Next Story

Tencent stock slips into weekend as 0700.HK lags tech gauge — what to watch before Monday

Go toTop